Volume Alert - JNJ 108.20 Johnson & Johnson $JNJ H
Post# of 129
Posted On: 11/08/2014 1:04:22 AM
Volume Alert - JNJ 108.20 Johnson & Johnson $JNJ Hit a high today of 109.03 Closing the day 11/07/14 at 108.20 -0.81 -0.74% With a day low of 107.92 and a total volume of 6,652,571.
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
New President and New Offices Signal New Era for New Jersey-based BNO
PR Newswire - Fri Nov 07, 5:36PM CST
Baldwin & Obenauf, Inc. (BNO), an award-winning creative agency with a roster of clients that includes Johnson & Johnson, MasterCard, and BASF, has named a new president and moved its headquarters to Somerville, NJ.
JNJ: 108.20 (-0.81)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.20 (-0.81), BAX: 70.61 (-0.99), PFE: 29.92 (-0.12), BMY: 58.32 (-0.14)
Final Glance: Medical Devices companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:
ZMH: 108.19 (-2.00), JNJ: 108.20 (-0.81), MDT: 68.10 (-0.64), BAX: 70.61 (-0.99)
Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition
PR Newswire - Fri Nov 07, 3:05PM CST
Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
JNJ: 108.20 (-0.81)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), GILD: 106.45 (-0.49), AZN: 72.88 (+0.03), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14), CELG: 106.45 (-0.69)
Midday Glance: Medical Devices companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top medical devices companies are down at 1 p.m.:
ZMH: 108.19 (-2.00), JNJ: 108.20 (-0.81), MDT: 68.10 (-0.64), BAX: 70.61 (-0.99)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.20 (-0.81), BAX: 70.61 (-0.99), PFE: 29.92 (-0.12), BMY: 58.32 (-0.14)
Early Glance: Pharmaceuticals companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.20 (-0.81), BAX: 70.61 (-0.99), PFE: 29.92 (-0.12), BMY: 58.32 (-0.14)
Early Glance: Medical Devices companies
AP - Fri Nov 07, 9:54AM CST
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:
ZMH: 108.19 (-2.00), JNJ: 108.20 (-0.81), MDT: 68.10 (-0.64), BAX: 70.61 (-0.99)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 65.75 (-3.22), JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), SHPG: 198.58 (-1.37), MRK: 59.34 (+0.08), AMGN: 160.25 (-0.10)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.20 (-0.81), ESRX: 77.87 (-0.05), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), ENTA: 43.33 (-0.17)
J&J Snack Foods posts 4Q profit
Automated Insights - Thu Nov 06, 4:48PM CST
PENNSAUKEN, N.J. (AP) _ J&J Snack Foods Corp. (JJSF) on Thursday reported profit of $22.2 million, or $1.19 per share, in its fiscal fourth quarter.
JNJ: 108.20 (-0.81), JJSF: 103.21 (-0.54)
Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting
Marketwired - Thu Nov 06, 3:20PM CST
Alios BioPharma, Inc., announced the upcoming presentation of preclinical data from two of its anti-hepatitis C virus (HCV) nucleotide analogs at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) beginning tomorrow in Boston. Data from two novel compounds -- AL-335, a potent uridine based nucleotide analog and AL-516, a potent guanosine based nucleotide analog -- will be presented in two poster sessions on Tuesday, November 11.
JNJ: 108.20 (-0.81)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), AZN: 72.88 (+0.03), AMAG: 34.95 (+0.83)
JNJ Recent Posts: http://investorshangout.com/Johnson--Johnson-JNJ-51518/
JNJ Johnson & Johnson Recent Headline News
New President and New Offices Signal New Era for New Jersey-based BNO
PR Newswire - Fri Nov 07, 5:36PM CST
Baldwin & Obenauf, Inc. (BNO), an award-winning creative agency with a roster of clients that includes Johnson & Johnson, MasterCard, and BASF, has named a new president and moved its headquarters to Somerville, NJ.
JNJ: 108.20 (-0.81)
Final Glance: Pharmaceuticals companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.20 (-0.81), BAX: 70.61 (-0.99), PFE: 29.92 (-0.12), BMY: 58.32 (-0.14)
Final Glance: Medical Devices companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:
ZMH: 108.19 (-2.00), JNJ: 108.20 (-0.81), MDT: 68.10 (-0.64), BAX: 70.61 (-0.99)
Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition
PR Newswire - Fri Nov 07, 3:05PM CST
Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
JNJ: 108.20 (-0.81)
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics' Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), GILD: 106.45 (-0.49), AZN: 72.88 (+0.03), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14), CELG: 106.45 (-0.69)
Midday Glance: Medical Devices companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top medical devices companies are down at 1 p.m.:
ZMH: 108.19 (-2.00), JNJ: 108.20 (-0.81), MDT: 68.10 (-0.64), BAX: 70.61 (-0.99)
Midday Glance: Pharmaceuticals companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.20 (-0.81), BAX: 70.61 (-0.99), PFE: 29.92 (-0.12), BMY: 58.32 (-0.14)
Early Glance: Pharmaceuticals companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.20 (-0.81), BAX: 70.61 (-0.99), PFE: 29.92 (-0.12), BMY: 58.32 (-0.14)
Early Glance: Medical Devices companies
AP - Fri Nov 07, 9:54AM CST
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:
ZMH: 108.19 (-2.00), JNJ: 108.20 (-0.81), MDT: 68.10 (-0.64), BAX: 70.61 (-0.99)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 65.75 (-3.22), JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), SHPG: 198.58 (-1.37), MRK: 59.34 (+0.08), AMGN: 160.25 (-0.10)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.20 (-0.81), ESRX: 77.87 (-0.05), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), ENTA: 43.33 (-0.17)
J&J Snack Foods posts 4Q profit
Automated Insights - Thu Nov 06, 4:48PM CST
PENNSAUKEN, N.J. (AP) _ J&J Snack Foods Corp. (JJSF) on Thursday reported profit of $22.2 million, or $1.19 per share, in its fiscal fourth quarter.
JNJ: 108.20 (-0.81), JJSF: 103.21 (-0.54)
Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting
Marketwired - Thu Nov 06, 3:20PM CST
Alios BioPharma, Inc., announced the upcoming presentation of preclinical data from two of its anti-hepatitis C virus (HCV) nucleotide analogs at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) beginning tomorrow in Boston. Data from two novel compounds -- AL-335, a potent uridine based nucleotide analog and AL-516, a potent guanosine based nucleotide analog -- will be presented in two poster sessions on Tuesday, November 11.
JNJ: 108.20 (-0.81)
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), AZN: 72.88 (+0.03), AMAG: 34.95 (+0.83)
(0)
(0)Johnson & Johnson (JNJ) Stock Research Links
Scroll down for more posts ▼